Treatment resistance in chronic lymphocytic leukemia - The role of the p53 pathway

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 510-513

  Zenz, Thorsten ^a   Mohr, Julia ^a   Edelmann, Jennifer ^a   Sarno, Antonio ^a   Hoth, Patrick ^a   Heuberger, Maria ^a   Helfrich, Hanne ^a   Mertens, Daniel ^a   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

17p deletion; CLL; Drug resistance; Genetics; p53; TP53 mutation

Indexed keywords

ALEMTUZUMAB; ATM PROTEIN; DNA; FLAVOPIRIDOL; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; MICRORNA; PROTEIN P53; STEROID;

ALLELE; ARTICLE; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA DAMAGE; DOWN REGULATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67650882993     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902763533     Document Type: Article

References (12)

1. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A. Cabot, G. et al. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, pp. 1580-1589.
2. Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C. Kitada, S. et al. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol, 25, pp. 799-804.
3. Zenz, T., Dohner, H. and Stilgenbauer, S. (2007) Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol, 20, pp. 439-453.
4. Austen, B., Skowronska, A., Baker, C., Powell, J. E., Gardiner, A. Oscier, D. et al. (2007) Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol, 25, pp. 5448-5457.
5. Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M. and Stankovic, T. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood, 98, pp. 814-822.
6. Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A. Wu, J. et al. (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol, 25, pp. 5616-5623.
7. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A. Benner et al. (2008) Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: Results from a detailed genetic characterization with long term follow-up. Blood, 112, pp. 3322-3329.
8. Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N. Wu et al. (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia, 23, pp. 117-124.
9. Rossi, D., Cerri, M., Dcambrogi, C., Sozzi, E., Cresta, S. Rasi, S. et al. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Ciin Cancer Res, 15, pp. 995-1004.
10. Kujawski, L., Ouillette, P., Erba, H., Saddler, C., Jakubowiak, A. Kaminski, M. et al. (2008) Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood, 112, pp. 1993-2003.
11. Zenz, T., Habe, S., Dcnzel, T., Winkler, D., Hallek, M. Hensel, M. et al. (2008) The activity of alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL: Final analysis from the CLL2H stxdy of the GCLLSG. Am Oncol, 19, p. v193.
12. Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A. Kienle, D. et al. (2008) MiR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. Blood